Trial Profile
A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary) ; Irinotecan; Temozolomide
- Indications Ewing's sarcoma
- Focus Registrational; Therapeutic Use
- Acronyms VITA
- Sponsors Gradalis
- 04 Apr 2023 Status changed from active, no longer recruiting to discontinued.
- 03 Feb 2021 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.
- 03 Feb 2021 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.